Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Trial Profile

Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Apr 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel; Ticagrelor; Warfarin
  • Indications Atrial fibrillation; Coronary artery disease
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top